From Discovery to GMP: Building Scalable Cell Therapy Manufacturing

Read Now

Over the past decade, our industry has witnessed the promise of cell and gene therapies. Patients with rare diseases or hard-to-treat diagnoses now have treatment options harnessing human cells and genes to alter disease. The accessibility of these therapies remains constrained not by what’s biologically possible, but how they are designed and manufactured.

The field has reached an inflection point. We’ve demonstrated the scientific foundation and its curative potential. To make advanced therapies sustainable as a pillar of medicine, we must make them more accessible. The companies that will define cell and gene therapy’s future will be those who can eliminate the distance between top science and efficient manufacturing.

This eBook brings together perspectives from Genetic Engineering News and ElevateBio to examine both the technical and operational realities shaping cell therapy today. From emerging innovations to persistent manufacturing challenges, the goal is to connect scientific progress with the systems required to scale it.

Traditional drug development has relied on siloed pathways, where therapeutics are designed and developed by one team and then manufactured by another. This approach is especially challenging in cell therapy, often leading to delays, setbacks, or outright failures. ElevateBio was built differently. Therapeutic design, development, and manufacturing operate as an integrated ecosystem, enabling tighter coordination and faster iteration.

The future of cell therapy depends on therapies designed with manufacturability in mind from the start. Process development, analytical strategy, and quality considerations must be embedded early, allowing manufacturing insights to inform development decisions in real time. This includes optimizing constructs, delivery systems, and processes to ensure scalability, reproducibility, and readiness for GMP production.

Looking beyond the science, a sustainable cell therapy ecosystem requires more than better therapeutics. It requires expanded treatment infrastructure, new commercial models, and systems capable of supporting broader patient access. But that ecosystem cannot scale on unreliable manufacturing.

As cell therapies expand into larger patient populations and new indications, the need for manufacturing designed for reliability and scale from day one becomes more urgent. The therapies being developed today have the potential to transform millions of lives—but only if the systems supporting them are built to deliver at scale.

Michael Paglia, Chief Technology Officer, ElevateBio

The post From Discovery to GMP: Building Scalable Cell Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.